Published in Ann N Y Acad Sci on June 01, 2005
Deconvolution of blood microarray data identifies cellular activation patterns in systemic lupus erythematosus. PLoS One (2009) 2.98
Interferon-inducible gene 202b controls CD8(+) T cell-mediated suppression in anti-DNA Ig peptide-treated (NZB × NZW) F1 lupus mice. Genes Immun (2011) 1.41
Dicer insufficiency and microRNA-155 overexpression in lupus regulatory T cells: an apparent paradox in the setting of an inflammatory milieu. J Immunol (2010) 1.13
The levels of sCD30 and of sCD40L in a group of patients with systemic lupus erythematodes and their diagnostic value. Clin Rheumatol (2006) 0.94
Therapeutic potential of CD8+ cytotoxic T lymphocytes in SLE. Autoimmun Rev (2008) 0.94
Increased Foxp3(+) CD4(+) regulatory T cells with intact suppressive activity but altered cellular localization in murine lupus. Am J Pathol (2008) 0.84
Fatigue in systemic lupus erythematosus. Int J Clin Rheumtol (2012) 0.84
Therapeutic effect of leflunomide on the development of experimental lupus nephritis in mice. Rheumatol Int (2010) 0.81
Induction of mucosal tolerance in SLE: a sniff or a sip away from ameliorating lupus? Clin Immunol (2008) 0.79
Implications of the parent-into-F1 model for human lupus pathogenesis: roles for cytotoxic T lymphocytes and viral pathogens. Curr Opin Rheumatol (2010) 0.78
P3 mAb: An Immunogenic Anti-NeuGcGM3 Antibody with Unusual Immunoregulatory Properties. Front Immunol (2012) 0.75
Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 40.32
CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol (2002) 12.73
Regulatory T cells: key controllers of immunologic self-tolerance. Cell (2000) 10.19
Regulatory T cells in autoimmmunity*. Annu Rev Immunol (2000) 9.36
CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum (2004) 3.36
Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J Immunol (2004) 3.15
Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun (2003) 2.81
T cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire. Annu Rev Immunol (2001) 2.51
CD4+CD25+ regulatory T cells cure murine colitis: the role of IL-10, TGF-beta, and CTLA4. J Immunol (2003) 2.19
CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis. Clin Exp Immunol (2005) 1.76
The specific regulation of immune responses by CD8+ T cells restricted by the MHC class Ib molecule, Qa-1. Annu Rev Immunol (2000) 1.68
Immunoregulatory role of CD1d in the hydrocarbon oil-induced model of lupus nephritis. J Immunol (2003) 1.44
Impairment of CD8+ T suppressor cell function in patients with active systemic lupus erythematosus. J Immunol (2001) 1.36
Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function. Hum Immunol (2004) 1.32
Repeated alpha-galactosylceramide administration results in expansion of NK T cells and alleviates inflammatory dermatitis in MRL-lpr/lpr mice. J Immunol (2003) 1.29
Ig-reactive CD4+CD25+ T cells from tolerized (New Zealand Black x New Zealand White)F1 mice suppress in vitro production of antibodies to DNA. J Immunol (2004) 1.28
Regulatory CD8+ T cells fine-tune the myelin basic protein-reactive T cell receptor V beta repertoire during experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2003) 1.27
CD1d deficiency exacerbates inflammatory dermatitis in MRL-lpr/lpr mice. Eur J Immunol (2004) 1.18
Vaccination with minigenes encoding V(H)-derived major histocompatibility complex class I-binding epitopes activates cytotoxic T cells that ablate autoantibody-producing B cells and inhibit lupus. J Exp Med (2002) 1.18
A cDNA clone encoding the mouse Qa-1a histocompatibility antigen and proposed structure of the putative peptide binding site. J Immunol (1993) 1.16
Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus. Arthritis Rheum (2001) 1.16
Overlap between molecular markers expressed by naturally occurring CD4+CD25+ regulatory T cells and antigen specific CD4+CD25+ and CD8+CD28- T suppressor cells. Hum Immunol (2004) 1.14
Induction of autoantibody production is limited in nonautoimmune mice. J Immunol (2002) 1.13
Molecular characterization of allospecific T suppressor and tolerogenic dendritic cells: review. Int Immunopharmacol (2005) 1.07
An integrated model of immunoregulation mediated by regulatory T cell subsets. Adv Immunol (2004) 1.00
The role of CD28 and CTLA4 in the function and homeostasis of CD4+CD25+ regulatory T cells. Novartis Found Symp (2003) 1.00
Differences between CD8+ T cells in lupus-prone (NZB x NZW) F1 mice and healthy (BALB/c x NZW) F1 mice may influence autoimmunity in the lupus model. Eur J Immunol (2004) 0.89
Peptides from Vh regions of antibodies to DNA activate T cell help to upregulate autoantibody synthesis. Lupus (1997) 0.81
A key role of leptin in the control of regulatory T cell proliferation. Immunity (2007) 3.71
An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness. Immunity (2010) 2.71
Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses. J Clin Invest (2003) 1.87
Balancing susceptibility to infection and autoimmunity: a role for leptin? Trends Immunol (2002) 1.84
Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia. Eur J Immunol (2010) 1.72
Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J Exp Med (2010) 1.70
A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum (2011) 1.70
Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. J Immunol (2005) 1.69
Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation. Ann Neurol (2011) 1.67
Leptin increase in multiple sclerosis associates with reduced number of CD4(+)CD25+ regulatory T cells. Proc Natl Acad Sci U S A (2005) 1.67
Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum (2009) 1.48
Organ-specific features of natural killer cells. Nat Rev Immunol (2011) 1.48
The intricate interface between immune system and metabolism. Trends Immunol (2004) 1.46
Leptin accelerates autoimmune diabetes in female NOD mice. Diabetes (2002) 1.43
Cutting edge: Regulatory T cells directly suppress B cells in systemic lupus erythematosus. J Immunol (2009) 1.41
Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia. J Immunol (2005) 1.35
Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFbeta-secreting CD8+ T cell suppressors. J Immunol (2005) 1.30
Leptin neutralization interferes with pathogenic T cell autoreactivity in autoimmune encephalomyelitis. J Clin Invest (2006) 1.25
ApoE-/-Fas-/- C57BL/6 mice: a novel murine model simultaneously exhibits lupus nephritis, atherosclerosis, and osteopenia. J Lipid Res (2007) 1.21
Regulatory T cells in obesity: the leptin connection. Trends Mol Med (2010) 1.21
The natural killer T cell ligand alpha-galactosylceramide prevents or promotes pristane-induced lupus in mice. Eur J Immunol (2005) 1.20
Leptin and Inflammation. Curr Immunol Rev (2008) 1.19
High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. Ann Rheum Dis (2011) 1.18
CD8+ T cell-mediated suppression of autoimmunity in a murine lupus model of peptide-induced immune tolerance depends on Foxp3 expression. J Immunol (2007) 1.18
Ischemic neurons recruit natural killer cells that accelerate brain infarction. Proc Natl Acad Sci U S A (2014) 1.16
TGF-beta 1 regulates lymphocyte homeostasis by preventing activation and subsequent apoptosis of peripheral lymphocytes. J Immunol (2003) 1.13
Neuronal phagocytosis by inflammatory macrophages in ALS spinal cord: inhibition of inflammation by resolvin D1. Am J Neurodegener Dis (2012) 1.12
Leptin and adipocytokines: bridging the gap between immunity and atherosclerosis. Curr Pharm Des (2007) 1.12
IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients. J Neuroinflammation (2010) 1.11
Mesenchymal stem cell population derived from human pluripotent stem cells displays potent immunomodulatory and therapeutic properties. Stem Cells Dev (2014) 1.10
pConsensus peptide induces tolerogenic CD8+ T cells in lupus-prone (NZB x NZW)F1 mice by differentially regulating Foxp3 and PD1 molecules. J Immunol (2008) 1.07
Leptin-induced mTOR activation defines a specific molecular and transcriptional signature controlling CD4+ effector T cell responses. J Immunol (2012) 1.07
Effect of an exogenous trigger on the pathogenesis of lupus in (NZB x NZW)F1 mice. Arthritis Rheum (2002) 1.06
CD8+ Tregs in lupus, autoimmunity, and beyond. Autoimmun Rev (2010) 1.04
Regulatory CD4 T cells: sensing the environment. Trends Immunol (2007) 1.03
Anti-DNA Ig peptides promote Treg cell activity in systemic lupus erythematosus patients. Arthritis Rheum (2008) 1.03
Cytokines in systemic lupus erythematosus. Curr Mol Med (2009) 1.03
Self-antigen recognition by TGF beta1-deficient T cells causes their activation and systemic inflammation. Lab Invest (2006) 1.01
Cutting edge: Leptin-induced RORγt expression in CD4+ T cells promotes Th17 responses in systemic lupus erythematosus. J Immunol (2013) 1.00
Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis. Arthritis Res Ther (2010) 0.98
IL-21 receptor expression determines the temporal phases of experimental autoimmune encephalomyelitis. Exp Neurol (2007) 0.98
Autoreactive T cells mediate NK cell degeneration in autoimmune disease. J Immunol (2006) 0.97
Leptin as a metabolic link to multiple sclerosis. Nat Rev Neurol (2010) 0.96
Manipulation of immune regulation in systemic lupus erythematosus. Autoimmun Rev (2005) 0.96
Protection against renal disease in (NZB x NZW)F(1) lupus-prone mice after somatic B cell gene vaccination with anti-DNA immunoglobulin consensus peptide. Arthritis Rheum (2007) 0.96
Cutting edge: fasting-induced hypoleptinemia expands functional regulatory T cells in systemic lupus erythematosus. J Immunol (2012) 0.95
Natural regulatory T cells in autoimmunity. Autoimmunity (2010) 0.94
CCL2 recruitment of IL-6-producing CD11b+ monocytes to the draining lymph nodes during the initiation of Th17-dependent B cell-mediated autoimmunity. Eur J Immunol (2008) 0.94
Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. Arthritis Rheum (2002) 0.93
Low physical activity is associated with proinflammatory high-density lipoprotein and increased subclinical atherosclerosis in women with systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2010) 0.92
Generation of mice with a conditional allele for transforming growth factor beta 1 gene. Genesis (2009) 0.92
Leptin modulates the survival of autoreactive CD4+ T cells through the nutrient/energy-sensing mammalian target of rapamycin signaling pathway. J Immunol (2010) 0.92
miRNA in systemic lupus erythematosus. Clin Immunol (2012) 0.91
Proinflammatory responses to self HLA epitopes are triggered by molecular mimicry to Epstein-Barr virus proteins in oligoarticular juvenile idiopathic arthritis. Arthritis Rheum (2002) 0.91
Blockade of programmed death-1 in young (New Zealand black x New Zealand white)F1 mice promotes the activity of suppressive CD8+ T cells that protect from lupus-like disease. J Immunol (2010) 0.91
Gene vaccination for the induction of immune tolerance. Ann N Y Acad Sci (2007) 0.90
Differences between CD8+ T cells in lupus-prone (NZB x NZW) F1 mice and healthy (BALB/c x NZW) F1 mice may influence autoimmunity in the lupus model. Eur J Immunol (2004) 0.89
Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling. Am J Neurodegener Dis (2012) 0.89
Leptin promotes lupus T-cell autoimmunity. Clin Immunol (2013) 0.88
Leptin signaling: A key pathway in immune responses. Curr Signal Transduct Ther (2009) 0.88
Prevalence of subclinical atherosclerosis is increased in systemic sclerosis and is associated with serum proteins: a cross-sectional, controlled study of carotid ultrasound. Rheumatology (Oxford) (2013) 0.87
Developing pulmonary vasculopathy in systemic sclerosis, detected with non-invasive cardiopulmonary exercise testing. PLoS One (2010) 0.87
Meta-immunological profiling of children with type 1 diabetes identifies new biomarkers to monitor disease progression. Diabetes (2013) 0.87
Modulation of p38 MAPK activity in regulatory T cells after tolerance with anti-DNA Ig peptide in (NZB x NZW)F1 lupus mice. J Immunol (2009) 0.85
The role of invariant natural killer T cells in lupus and atherogenesis. Immunol Res (2006) 0.84
Blockade of programmed death-1 in young (New Zealand Black x New Zealand White)F1 mice promotes the suppressive capacity of CD4+ regulatory T cells protecting from lupus-like disease. J Immunol (2013) 0.82
Gender-Based Differences in Leptinemia in Healthy Aging, Non-obese Individuals Associate with Increased Marker of Oxidative Stress. Int J Clin Exp Med (2008) 0.82
Identification and characterization of SmD183-119-reactive T cells that provide T cell help for pathogenic anti-double-stranded DNA antibodies. Arthritis Rheum (2003) 0.82
Cutaneous vasculitis in breast cancer treated with chemotherapy. Clin Immunol (2008) 0.81
Tuning immune suppression in systemic autoimmunity with self-derived peptides. Inflamm Allergy Drug Targets (2008) 0.80
Potential for anti-DNA immunoglobulin peptide therapy in systemic lupus erythematosus. Expert Opin Biol Ther (2009) 0.80
Epigenetic dysregulation in systemic lupus erythematosus. Autoimmunity (2013) 0.80
Mimicking self-antigens with synthetic peptides in systemic autoimmune rheumatic diseases. Curr Clin Pharmacol (2009) 0.79
Regulatory T cells in systemic lupus erythematosus (SLE); role of peptide tolerance. Autoimmun Rev (2011) 0.78
New therapies in SLE. Recent Pat Inflamm Allergy Drug Discov (2008) 0.77
Common variable immunodeficiency: two mutations are better than one. J Clin Invest (2013) 0.77
TGFbeta1 deficiency does not affect the generation and maintenance of CD4+CD25+FOXP3+ putative Treg cells, but causes their numerical inadequacy and loss of regulatory function. Clin Immunol (2008) 0.77
Preclinical studies with synthetic peptides in systemic lupus erythematosus. Front Biosci (Landmark Ed) (2012) 0.77
Novel approaches to lupus drug discovery using stem cell therapy. Role of mesenchymal-stem-cell-secreted factors. Expert Opin Drug Discov (2014) 0.76
In vivo veritas, in vitro artificia. Trends Mol Med (2012) 0.76
Leptin in non-autoimmune inflammation. Inflamm Allergy Drug Targets (2009) 0.76
Tolerance induced by anti-DNA Ig peptide in (NZB×NZW)F1 lupus mice impinges on the resistance of effector T cells to suppression by regulatory T cells. Clin Immunol (2011) 0.75
Putting together the autoimmunity puzzle. J Clin Invest (2015) 0.75
Dyspnea, hemoptysis, and perihilar infiltrates in a 35-year-old man. Chest (2005) 0.75
Autoimmunity and celiac disease. Mini Rev Med Chem (2008) 0.75
Targeting BLyS in systemic lupus erythematosus. Recent Pat Inflamm Allergy Drug Discov (2012) 0.75
Antibody-based therapies in systemic lupus erythematosus. Mini Rev Med Chem (2009) 0.75
Regulatory CD4+ T cells promote B cell anergy in murine lupus. J Immunol (2014) 0.75
Serum IFN-λ1 is abnormally elevated in rheumatoid arthritis patients. Autoimmunity (2012) 0.75
The Proteomic Landscape of Human Ex Vivo Regulatory and Conventional T Cells Reveals Specific Metabolic Requirements. Immunity (2016) 0.75